Market closed
CytomX/$CTMX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About CytomX
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Ticker
$CTMX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
120
Website
CytomX Metrics
BasicAdvanced
$61M
2.01
$0.38
1.04
-
Price and volume
Market cap
$61M
Beta
1.04
52-week high
$5.06
52-week low
$0.40
Average daily volume
1.2M
Financial strength
Current ratio
1.251
Quick ratio
1.209
Long term debt to equity
-929.825
Total debt to equity
-2,058.114
Management effectiveness
Return on assets (TTM)
9.69%
Return on equity (TTM)
-133.06%
Valuation
Price to earnings (TTM)
2.007
Price to revenue (TTM)
0.463
Price to book
-133.05
Price to tangible book (TTM)
-30.51
Price to free cash flow (TTM)
-0.739
Growth
Revenue change (TTM)
36.45%
Earnings per share change (TTM)
-3,874.57%
3-year revenue growth (CAGR)
54.69%
3-year earnings per share growth (CAGR)
-40.66%
What the Analysts think about CytomX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for CytomX stock.
CytomX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
CytomX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
CytomX News
AllArticlesVideos
CytomX Therapeutics Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna at AACR Annual Meeting
GlobeNewsWire·4 days ago
CytomX Therapeutics, Inc. (CTMX) Q4 2024 Earnings Call Transcript
Seeking Alpha·2 months ago
CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for CytomX stock?
CytomX (CTMX) has a market cap of $61M as of May 03, 2025.
What is the P/E ratio for CytomX stock?
The price to earnings (P/E) ratio for CytomX (CTMX) stock is 2.01 as of May 03, 2025.
Does CytomX stock pay dividends?
No, CytomX (CTMX) stock does not pay dividends to its shareholders as of May 03, 2025.
When is the next CytomX dividend payment date?
CytomX (CTMX) stock does not pay dividends to its shareholders.
What is the beta indicator for CytomX?
CytomX (CTMX) has a beta rating of 1.04. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.